# Preference for a Prefilled Syringe or Smartject™ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027)

> **NCT02155335** · PHASE4 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 100 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** Prefilled Syringe delivery of Golimumab
- **DRUG:** Smartject Device delivery of Golimumab

## Key facts

- **NCT ID:** NCT02155335
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-01
- **Primary completion:** 2015-10-05
- **Final completion:** 2015-10-05
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2019-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02155335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02155335, "Preference for a Prefilled Syringe or Smartject™ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027)". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02155335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*